PHOENIX, Aug. 22,
2023 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:
TRIN) ("Trinity" or the "Company"), a leading provider of
diversified financial solutions to growth-stage companies, today
announced the commitment of $12
million in growth capital to Delphinus Medical Technologies,
Inc. ("Delphinus"), a medical imaging company that has developed
SoftVue™, a dense breast screening innovation that increases cancer
detection and decreases unnecessary call backs, while delivering a
comfortable patient experience.
The SoftVue™ 3D Whole Breast Ultrasound Tomography System was
approved by the U.S. Food & Drug Administration (FDA) in
October 2021. This disruptive
technology not only redefines the standards for early breast cancer
detection but also enhances patient comfort, with 95% of women who
have experienced SoftVue indicating they would recommend the exam
to other women. Delphinus continues to expand its commercial
foundation and most recently added Corewell Health as a commercial
site to build a robust dense breast screening program to benefit
patients.
"We are excited to be a part of Delphinus' journey as they
innovate life-saving medical imaging technology," said Lauren Cosentino, Managing Director, Life
Sciences at Trinity. "We believe in their team and are excited to
help accelerate their growth trajectory."
This growth capital will enable the team at Delphinus to
continue to scale operations and broaden their impact in the global
healthcare community.
"Mammography is not enough to address the screening needs of
dense breast patients," said Mark J Forchette, President and CEO of
Delphinus Medical Technologies. "The addition of SoftVue for dense
breast screening implements a comprehensive solution for sites to
transform the clinical experience of their patients. Our
relationship with Trinity Capital helps us make impactful
investments to help sites embrace this innovation and serve the
unmet patient needs that SoftVue was designed to address. We are
thrilled to work together."
About Trinity Capital Inc.
Trinity Capital
Inc. (Nasdaq: TRIN), an internally managed business
development company, is a leading provider of diversified financial
solutions to growth-stage companies with institutional equity
investors. Trinity Capital's investment objective is to
generate current income and, to a lesser extent, capital
appreciation through investments, including term loans and
equipment financings and equity-related investments. Trinity
Capital believes it is one of only a select group of specialty
lenders that has the depth of knowledge, experience and track
record in lending to growth stage companies. For more information,
please visit the Company's website at www.trinitycap.com.
About Delphinus Medical Technologies,
Inc.
Headquartered in Novi,
Mich., Delphinus Medical Technologies, Inc. is a pioneering
medical imaging company that has developed SoftVue™, featuring the
first circular array transducer technology. The patented technology
is a 3D whole breast ultrasound tomography system that delivers no
radiation, requires no compression, and images the entire breast
with a single scan.
SoftVue™ has previously received three 510(k)s, and the PMA
approval for dense breast screening adjunct to mammography expands
the company's existing platform of approvals to include breast
cancer screening in asymptomatic women with dense breast parenchyma
after confirmation that the breast density composition is BI-RADS c
or d at the time of screening mammography. The device is not
intended to be used as a replacement for screening mammography.
SoftVue™ can be used at the same visit as screening mammography,
and the SoftVue™ images are intended to be interpreted with the
mammogram results to enhance screening.
Delphinus was founded as a spin out of the Karmanos Cancer
Institute in Detroit. For more
information, visit www.delphinusmt.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-12-million-growth-capital-to-delphinus-medical-technologies-inc-301904087.html
SOURCE Trinity Capital Inc.